Neoantigen Cancer Vaccine Helps BioNTech Advance Oncology Ambitions
Encouraging 50% Response Rate
After many years of failures and setbacks, neoantigen-targeting immunotherapies are gaining momentum, with BioNTech and Roche among the frontrunners.
You may also be interested in...
CAR-T has revolutionized the treatment options for blood cancers but its application for solid tumors has fallen short. The German biotech hopes that by combining a CAR-T cell therapy with an mRNA vaccine could be a gamechanger.
CD47 was once seen as one of the hottest properties in immunotherapy, but multiple setbacks have tempered enthusiasm for targeting the ‘don’t eat me’ cell surface protein. I-Mab and Gilead are just two casualties.
The ex-chief medical officer at Novartis is now CEO at the UK-based biotech, which he he told Scrip could have a ‘transformational’ therapy to protect patients after a heart attack.